论文部分内容阅读
本研究旨在确定新诊断的帕金森病（PD）患者应用卡麦角林（cabeedn，CBG）作为首选药物与单一首选左旋多巴治疗比较能否延缓运动症状波动的发生。并对两药在第1年治疗期间的疗效进行比较。病人和方法413例自愿进人基础研究期的患者，采用双百平行组研究方法。功能障碍严重程度
The purpose of this study was to determine whether the use of cabeedn (CBG) as the drug of choice in patients with newly diagnosed Parkinson’s disease (PD) compared with single-choice levodopa treatment could delay the onset of motor symptoms. The efficacy of the two drugs during the first year of treatment was compared. Patients and Methods A total of 413 patients who volunteered for the basic study period were enrolled in a two-hundred parallel study. Dysfunction severity